A Jacksonville-area clinical research group is working to find a new path to lasting weight loss beyond the use of Glucagon-like peptide-1 (GLP-1) drugs. The drugs, which were originally developed to treat diabetes, often have a satiety effect and help people lose weight because they don't eat as much. However, these results can be reversed, with some people finding it harder to feel full and easier to overeat. Dr. Michael Koren, who has worked in clinical research for 35 years, is now studying an "amylin agonist" that takes a different approach to appetite control. If successful, this could be a game-changer for people who have plateaued on GLP-one medications or have regained weight after stopping them.